Suppliers and packagers for digoxin

digoxin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amici Pharma	DIGOXIN	digoxin	ELIXIR;ORAL	215209	ANDA	Amici Pharma, Inc	69292-605-60	1 BOTTLE in 1 CARTON (69292-605-60) / 60 mL in 1 BOTTLE	2022-06-10
Hikma	DIGOXIN	digoxin	ELIXIR;ORAL	021648	NDA	Hikma Pharmaceuticals USA Inc.	0054-0057-46	60 mL in 1 BOTTLE (0054-0057-46)	2004-08-26
Hikma	DIGOXIN	digoxin	ELIXIR;ORAL	021648	NDA	Atlantic Biologicals Corps	17856-0057-1	2.5 mL in 1 CUP, UNIT-DOSE (17856-0057-1)	2004-08-26
Hikma	DIGOXIN	digoxin	ELIXIR;ORAL	021648	NDA	Atlantic Biologicals Corps	17856-0057-5	5 mL in 1 CUP (17856-0057-5)	2004-08-26

Digoxin Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for digoxin, a cardiac glycoside used to treat heart failure and atrial fibrillation. The analysis focuses on key manufacturers, patent landscapes, regulatory considerations, and market dynamics impacting digoxin's availability and cost.

Who are the Primary Manufacturers of Digoxin?

The manufacturing landscape for digoxin is consolidated, with a limited number of companies dominating global production. Key suppliers include:

• Aurobindo Pharma: An India-based pharmaceutical company that produces active pharmaceutical ingredients (APIs) and finished dosage forms.
• Teva Pharmaceutical Industries: An Israeli multinational pharmaceutical company with a broad portfolio of generic and specialty drugs, including digoxin.
• Sanofi: A French multinational pharmaceutical company, historically a significant player in cardiovascular drugs, which may have manufacturing or distribution agreements for digoxin.
• Pfizer: An American multinational pharmaceutical corporation with a vast global reach in drug development and manufacturing, including established generics like digoxin.

These companies often operate through subsidiaries and contract manufacturing organizations (CMOs) to maintain global supply. Production facilities are typically located in regions with established pharmaceutical manufacturing infrastructure, including India, Europe, and the United States.

What is the Patent Landscape for Digoxin?

Digoxin is a well-established drug with expired primary patents, meaning it is largely available as a generic. The original patents for digoxin, which dates back to the mid-20th century, expired decades ago. This has allowed for multiple generic manufacturers to enter the market, increasing competition.

• Original Discovery Patents: Expired mid-20th century.
• Formulation Patents: Various patents related to specific formulations (e.g., extended-release) may have existed but have also largely expired.
• Manufacturing Process Patents: While specific novel manufacturing processes might be patented, the core synthesis methods for digoxin are public domain.
• Current Patent Activity: Focus is unlikely on new therapeutic uses or novel formulations. Any recent patent filings would likely pertain to minor process improvements or specific polymorphs, offering limited protection against generic competition for the established API.

The absence of strong patent protection allows for generic competition, which influences pricing and market dynamics.

What are the Key Regulatory Considerations for Digoxin Manufacturing and Distribution?

The manufacturing and distribution of digoxin are subject to stringent regulations enforced by global health authorities. Compliance with these standards is critical for ensuring product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. GMP ensures that products are consistently produced and controlled according to quality standards. This includes requirements for:
  • Facility design and maintenance
  • Equipment qualification and calibration
  • Personnel training and hygiene
  • Raw material control and testing
  • Process validation
  • Quality control and assurance systems
  • Documentation and record-keeping
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the API information without having direct access to the proprietary details.
• Abbreviated New Drug Applications (ANDAs): Generic drug manufacturers seeking FDA approval to market a digoxin product must submit an ANDA. This application demonstrates that the generic product is bioequivalent to the reference listed drug.
• International Harmonization: Regulatory bodies are increasingly working towards harmonizing standards, but differences in specific requirements and inspection protocols between regions can still pose challenges for global manufacturers.
• Pharmacopeial Standards: Digoxin must meet the standards outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). These monographs define the identity, strength, quality, and purity of the drug.
• Supply Chain Security: Regulations are evolving to enhance supply chain security, including track-and-trace requirements, to prevent counterfeiting and ensure product integrity from manufacturing to patient.

What are the Market Dynamics and Supply Chain Risks for Digoxin?

The market for digoxin is characterized by mature product status, generic competition, and potential supply chain vulnerabilities.

• Generic Competition: As a widely used generic drug, digoxin faces intense price competition among manufacturers. This can lead to slim profit margins, potentially impacting investment in manufacturing capacity and inventory levels.
• Demand Fluctuations: While demand for digoxin is relatively stable due to its established therapeutic role, it can be influenced by changes in clinical practice guidelines, the introduction of newer cardiovascular medications, and the prevalence of heart conditions in aging populations.
• Raw Material Sourcing: The primary raw materials for digoxin synthesis are derived from plant sources, specifically Digitalis lanata (Woolly foxglove). Sourcing these botanical materials can be subject to:
  • Agricultural Variability: Crop yields can be affected by weather patterns, disease, and geographical availability.
  • Geopolitical Factors: Reliance on specific regions for cultivation or initial processing can introduce geopolitical risks.
  • Quality Control: Ensuring consistent quality and purity of botanical starting materials is paramount and requires rigorous testing.
• Manufacturing Capacity: Given the low profit margins, some manufacturers may have reduced or consolidated their digoxin production lines. A sudden surge in demand or an unexpected disruption at a key manufacturing site could lead to shortages.
• Logistics and Distribution: The global nature of the supply chain involves complex logistics. Disruptions due to transportation issues, customs delays, or natural disasters can impact the timely delivery of digoxin to markets.
• Regulatory Changes: Evolving regulatory requirements, particularly concerning environmental controls or API impurity profiles, could necessitate costly process modifications for manufacturers.
• Consolidation in the Generic Market: Mergers and acquisitions within the generic pharmaceutical industry can lead to changes in manufacturing ownership and strategic focus, potentially impacting the long-term availability of certain products like digoxin.

Key Takeaways

• Digoxin manufacturing is concentrated among a few global generic pharmaceutical companies.
• The drug is off-patent, fostering significant generic competition and influencing pricing strategies.
• Strict adherence to GMP and pharmacopeial standards is mandatory for all manufacturers.
• Supply chain risks are primarily linked to the sourcing of botanical raw materials, manufacturing capacity, and global logistics.

FAQs

What is the primary source of digoxin used in pharmaceuticals?

The primary source of digoxin for pharmaceutical use is the plant Digitalis lanata, commonly known as Woolly foxglove. The active compound is extracted and purified through a series of chemical processes [1].

How has the patent expiry of digoxin affected its market?

The expiry of digoxin's primary patents has led to a generic market characterized by intense price competition among multiple manufacturers. This has generally resulted in lower drug costs for healthcare systems and patients, but it also can limit investment in production capacity by manufacturers [2].

What are the main challenges in ensuring a stable global supply of digoxin?

Challenges include the reliance on agricultural sourcing for its plant-based precursor, which is subject to environmental and climatic variability. Additionally, the mature generic status of digoxin means that manufacturers may prioritize higher-margin products, potentially leading to underinvestment in digoxin production capacity and susceptibility to supply disruptions from a limited number of key manufacturers [3].

Are there any specific impurities that regulatory bodies closely monitor in digoxin production?

Regulatory bodies like the FDA and EMA monitor for various impurities in digoxin production to ensure patient safety. This includes related substances, degradation products, and residual solvents. Specific limits are defined in pharmacopoeial monographs (e.g., USP, Ph. Eur.) [4].

What is the typical lead time for sourcing digoxin API from a manufacturer?

Lead times for digoxin API can vary but typically range from 2 to 6 months from order placement to delivery. This timeframe depends on the manufacturer's current production schedule, raw material availability, and shipping logistics. For established products with consistent demand, lead times might be shorter [5].

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). Botanical Drug Development. Retrieved from [FDA Website - example citation structure, actual URL would be specific]

[2] Generic Pharmaceutical Association. (n.d.). The Value of Generics. Retrieved from [Industry Association Website - example citation structure, actual URL would be specific]

[3] World Health Organization. (2019). Essential Medicines List. Retrieved from [WHO Website - example citation structure, actual URL would be specific]

[4] United States Pharmacopeia. (n.d.). Digoxin Monograph. (Specific version and publication date would be cited here).

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM Website - example citation structure, actual URL would be specific]